MedTrace Logo

Efficacy of LCQ908 on Cardiovascular Risk

NCT01474434 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-04-14

Study results available
· View outcomes & findings →

Summary

This is a study designed to evaluate the potential for the pradigastat (LCQ908) to impact cardiovascular risk.

Conditions

Interventions

DRUG

pradigastat (LCQ908)

pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.

DRUG

Placebo

matching placebo tablets

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01474434 on ClinicalTrials.gov